Disrupting astrocyte–tumor cell interactions, targeting key signaling pathways such as STAT3, CHI3L1, and PPAR-gamma, and developing microRNA-based therapies are promising strategies for inhibiting astrocyte-mediated tumor progression. The gene discussed is STAT3; the disease is neoplasm.